Baird analyst David Rescott raised the firm’s price target on Edwards Lifesciences to $100 from $85 and keeps an Outperform rating on the shares. The firm said management didn’t appear any more bullish on growth outlook for TAVR given a competitor’s delay but still, the company remains an attractive growth asset backed by a durable TAVR segment and emerging/inflecting TMTT bucket.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences Corp. (EW) Q4 Earnings Cheat Sheet
- Wells upgrades Edwards Lifesciences, says tricuspid opportunity underappreciated
- Edwards Lifesciences upgraded to Overweight from Equal Weight at Wells Fargo
- Edwards Lifesciences earns FDA approval for Evoque tricuspid valve
- Early notable gainers among liquid option names on January 31st
